A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCS
- Conditions
- Gastric carcinoma stadium Ib-IVaMedDRA version: 9.1Level: LLTClassification code 10017770Term: Gastric carcinomaMedDRA version: 9.1Level: LLTClassification code 10008452Term: Chemotherapy multiple agents systemic
- Registration Number
- EUCTR2007-007273-23-NL
- Lead Sponsor
- Jeroen Bosch Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Ib-IVa histological proven resectable gastric adenocarcinoma
WHO < or = 1
Age > or = 18 years
No prior radio- or chemotherapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Ia gastric cancer
Other histological type than adenocarcinoma
Distant metastases
Inoperable patients
Other current serious illness or medical conditions
Known hypersensitivity to Docetaxel/Taxotere
Pregnant or lactating women
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method